Can your service accommodate loss-of-function DNMT3A mutations, which are often "undruggable"?

Absolutely. We use a synthetic lethality identification approach. By testing your small molecules against cell lines carrying specific DNMT loss-of-function mutations, we can identify compounds that selectively kill these cells by targeting a synthetic lethal partner, providing a powerful, novel mechanism for challenging cancer subtypes.

Do you analyze DNMT activity in primary tissue samples?

Yes, we specialize in maximizing output from challenging, limited samples. We use highly sensitive, non-radioactive micro-assays that require minimal nuclear extract, allowing us to generate robust DNMT/TET activity profiles from primary tissue samples.

DNA Methyltransferases & Demethylation Enzyme Activity/Expression Analysis Service

Creative Biolabs' service furnishes quantitative, high-resolution analytical capabilities for DNA Methyltransferases (DNMTs) and TET Demethylation enzymes. This platform provides scientific investigators with the requisite precise kinetic constants necessary for the rigorous validation of small molecule selectivity across all principal isoforms, including DNMT1, 3A, 3B, and TET enzymes. Consequently, clients secure exceptionally robust mechanistic data, sophisticated screening results concerning synergy with critical co-targets, and exhaustive expression profiling (both mRNA and protein), thereby facilitating accelerated compound prioritization and an enhanced comprehension of epigenetic modulation within complex biological models.

Mapping DNA Methyltransferases & Demethylation Enzyme Dynamics

DNA methylation constitutes a critical, reversible epigenetic modification, regulated by 'writer' DNMTs and 'eraser' TET enzymes. Aberrant DNMT expression frequently correlates with neoplastic transformation and adverse outcomes. Consequently, targeted inhibition of these regulatory enzymes, often in synergistic regimens with agents like PARP inhibitors, presents a promising strategy to precisely modulate pathway activity and facilitate the reactivation of silenced tumor-suppressor genes.

Prospective clients are encouraged to submit a consultation request for an in-depth assessment of service customization potential tailored to specific project needs.

Fig 1. DNMTs play different roles in cancers. (OA Literature)

Fig.1 The DNMT paradox and the different roles of DNMTs in various cancers in mammals. ¹

What We Can Offer

Ready for Combination Strategies

Pre-validated, high-throughput screening platform for synergistic studies with key co-targets (e.g., Platinum-like compounds, PARP inhibitors, immune pathway modulators, HDACi) to advance your compound's mechanistic profile.

Customized Assay Development

Complete flexibility to tailor the service, including custom substrate design, optimization of enzyme source (recombinant or nuclear extract), and specific post-translational modification analysis (e.g., DNMT1 S154 phosphorylation) to fit your project's unique mechanistic requirements.

Biomarker and Prognostic Validation

Robust, quantitative methods (qPCR/ELISA) to correlate enzyme expression and activity with pre-clinical data, aiding in compound prioritization and mechanism of action (MOA) substantiation.

Well-Established Quality System

Implementation of Quality-by-Design (QbD) principles across assay development and execution, ensuring highly reliable, reproducible, and traceably documented results for every Creative Biolabs project.

How Creative Biolabs Can Assist Your Project

Highlights

Quantitative Focus

We deliver absolute quantification in true kinetic constants, which is the gold standard required for advanced mechanistic publications and detailed data packages, unlike many assays that only offer relative fold-changes.

Combination Therapy Readiness

Our screening platform is pre-optimized to test synergism with key agents, including platinum-like compounds/chemotherapy, PARP Inhibitors, and Immune Pathway Modulators (e.g., enhancing IFNγ-mediated responses), giving you a head start on pre-clinical optimization.

Biomarker Precision

We offer validated assays for post-translational modifications (like DNMT1 S154 phosphorylation) and protein abundance, supporting the crucial compound prioritization needed for target engagement studies.

Proprietary Control Panels

Use of our validated, in-house DNMT and TET small-molecule inhibitors ensures internal assay quality control and robust data interpretation, eliminating experimental artifacts.

To fully ascertain the distinct advantages provided by Creative Biolabs, interested parties are advised to initiate a formal request.

Customer Reviews

FAQs

Related Services

Histone Deacetylase (HDAC) Panel Screening Service

Comprehensive histone deacetylase (HDAC) Profiling provides full selectivity screening against all four HDAC classes (I, II, III, IV) to determine inhibitor potency and specificity, advancing epigenetic therapeutic development.

Learn More →

Methyltransferase Panel Screening Service

Dedicated EZH2/PRC2 complex profiling service, measuring Ki and IC50 values against key HMT isoforms. Essential for validating small molecule inhibitors and understanding polycomb-mediated repression mechanisms.

Learn More →

How to Contact Us

Creative Biolabs' DNA methyltransferases & demethylation enzyme activity/expression analysis service offers quantitative kinetic data, isoform-specific selectivity, and industry-leading support for complex combination synergy screening, driving your therapeutic discovery forward. To learn more about how our advanced analysis platforms can be tailored to your unique research needs, please reach out to our team of experts.